Nos patients témoignent
Catherine,
patiente à Gustave Roussy

Nos patients témoignent
Brigitte,
Patiente à Gustave Roussy

Nos patients témoignent
Tommy,
Père de Wyatt, en rémission depuis 2022

Gustave Roussy: 1st hospital to join Cancer@Work

As Europe's leading cancer centre, Gustave Roussy is now the first hospital to have joined the Cancer@Work corporate club, a public-interest association set up in 2012, dedicated to the subject of cancer and illness in the workplace.

Gustave Roussy is committed to setting up initiatives to help employees affected by cancer to integrate, stay in work and improve their quality of life at work.

As a public health player, Gustave Roussy attaches great importance to health democracy. This term covers patients' rights and the desire to involve all players in the healthcare system in the development and implementation of healthcare policies. In line with one of the recommendations of the French National Authority for Health (HAS), which aims to support and encourage the involvement of patients in the world of healthcare, Gustave Roussy has been working for several years to encourage the creation of spaces and bodies for the involvement of patients and their carers.

 Practical information

• Getting to Gustave Roussy
• Getting to Chevilly-Larue
• Maps of Gustave Roussy
• Practical services
• Accommodation

Villejuif, 12 March 2024

The Lancet
A clinical trial proves the efficacy of sunitinib in the treatment of rare neuroendocrine tumors

Led by Dr. Éric Baudin, head of Gustave Roussy’s endocrine tumors committee, the European trial FIRSTMAPP is the first-ever randomized clinical trial concerning phaeochromocytomas and paragangliomas, rare neuroendocrine tumors. The results, published in February 2024 in The Lancet, show the efficacy of sunitinib, a tyrosine kinase inhibitor.